2444-054X
2444-054X
S2444-054X2022000200267
10.24875/ciru.20001318
España
España
España
España
España
España
00
04
2022
00
04
2022
90
2
267
277
[
2011
11
12
12
865-78
]
[
2005
23
23
23
5357-64
]
[
ESMO Guidelines Committee
2017
28
suppl 4
suppl 4
iv147-8
]
[
2011
312
1
1
43-54
]
[
2016
238
4
4
543-9
]
[
2017
15
1
1
113
]
[
2017
35
15
15
1713-20
]
[
2019
4
24
]
[
2008
216
1
1
64-74
]
[
2006
368
9544
9544
1329-38
]
[
2013
381
9863
9863
295-302
]
[
Avapritinib. Ficha técnica [Internet]
]
[
2020
21
7
7
923-34
]
[
2017
285-90
]
[
2009
208
80-6
]
[
2017
214
3
3
538-46
]
[
2015
29
2
2
355-67
]
[
2015
262
5
5
831-40
]
[
]
[
2008
32
1021-8
]
[
2014
21
8
8
2620
]
[
2019
13
3
3
491-4
]
[
2018
3
6
]
[
2014
203
2
2
306-14
]
[
2007
25
1753-59
]
[
2020
25
1
1
497-507
]
[
2004
18
6
6
924-30
]
[
2019
23
2
2
270-9
]
[
2014
21
11
11
3429-38
]
[
2018
3
71
]
[
2007
13
157-60
]
[
2005
29
2
2
203-7
]
[
2019
19
1
1
121
]
[
2020
46
6
6
1124-30
]
[
2019
62
537-41
]
[
2019
62
540-1
]
[
2019
23
501-2
]
[
2019
23
395
]
[
2013
17
571-4
]
[
2019
49
6
6
460-6
]
[
2019
11
424
]
[
2000
13
577-85
]
[
2015
21
1845-50
]
[
2011
58
865-8
]
[
2018
24
18
18
1925-41
]
[
2018
29
suppl 4
suppl 4
iv68-78
]
[
2014
80
9
9
890-5
]
[
2014
92
4
4
289-90
]
[
2012
118
3571-8
]
[
2007
245
347-52
]
[
2014
40
4
4
412-9
]
[
2015
22
9
9
2948-57
]
[
2014
37
1
1
132-9
]
[
2007
12
3
3
212-7
]
[
2012
18
42
42
6134-40
]
[
2019
19
2939-43
]